Cargando…

Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events

A mycoplasma contamination event in a biomanufacturing facility can result in costly cleanups and potential drug shortages. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and penetrate the standard 0.2‐µm filters used in the clarification of harvested cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Fratz‐Berilla, Erica J., Angart, Phillip, Graham, Ryan J., Powers, David N., Mohammad, Adil, Kohnhorst, Casey, Faison, Talia, Velugula‐Yellela, Sai Rashmika, Trunfio, Nicholas, Agarabi, Cyrus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496122/
https://www.ncbi.nlm.nih.gov/pubmed/32436993
http://dx.doi.org/10.1002/bit.27436
_version_ 1783583028048560128
author Fratz‐Berilla, Erica J.
Angart, Phillip
Graham, Ryan J.
Powers, David N.
Mohammad, Adil
Kohnhorst, Casey
Faison, Talia
Velugula‐Yellela, Sai Rashmika
Trunfio, Nicholas
Agarabi, Cyrus
author_facet Fratz‐Berilla, Erica J.
Angart, Phillip
Graham, Ryan J.
Powers, David N.
Mohammad, Adil
Kohnhorst, Casey
Faison, Talia
Velugula‐Yellela, Sai Rashmika
Trunfio, Nicholas
Agarabi, Cyrus
author_sort Fratz‐Berilla, Erica J.
collection PubMed
description A mycoplasma contamination event in a biomanufacturing facility can result in costly cleanups and potential drug shortages. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and penetrate the standard 0.2‐µm filters used in the clarification of harvested cell culture fluid. Previously, we reported a study regarding the ability of Mycoplasma arginini to persist in a single‐use, perfusion rocking bioreactor system containing a Chinese hamster ovary (CHO) DG44 cell line expressing a model monoclonal immunoglobulin G 1 (IgG1) antibody. Our previous work showed that M. arginini affects CHO cell growth profile, viability, nutrient consumption, oxygen use, and waste production at varying timepoints after M. arginini introduction to the culture. Careful evaluation of certain identified process parameters over time may be used to indicate mycoplasma contamination in CHO cell cultures in a bioreactor before detection from a traditional method. In this report, we studied the changes in the IgG1 product quality produced by CHO cells considered to be induced by the M. arginini contamination events. We observed changes in critical quality attributes correlated with the duration of contamination, including increased acidic charge variants and high mannose species, which were further modeled using principal component analysis to explore the relationships among M. arginini contamination, CHO cell growth and metabolites, and IgG1 product quality attributes. Finally, partial least square models using NIR spectral data were used to establish predictions of high levels (≥10(4) colony‐forming unit [CFU/ml]) of M. arginini contamination, but prediction of levels below 10(4) CFU/ml were not reliable. Contamination of CHO cells with M. arginini resulted in significant reduction of antibody product quality, highlighting the importance of rapid microbiological testing and mycoplasma testing during particularly long upstream bioprocesses to ensure product safety and quality.
format Online
Article
Text
id pubmed-7496122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74961222020-09-25 Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events Fratz‐Berilla, Erica J. Angart, Phillip Graham, Ryan J. Powers, David N. Mohammad, Adil Kohnhorst, Casey Faison, Talia Velugula‐Yellela, Sai Rashmika Trunfio, Nicholas Agarabi, Cyrus Biotechnol Bioeng ARTICLES A mycoplasma contamination event in a biomanufacturing facility can result in costly cleanups and potential drug shortages. Mycoplasma may survive in mammalian cell cultures with only subtle changes to the culture and penetrate the standard 0.2‐µm filters used in the clarification of harvested cell culture fluid. Previously, we reported a study regarding the ability of Mycoplasma arginini to persist in a single‐use, perfusion rocking bioreactor system containing a Chinese hamster ovary (CHO) DG44 cell line expressing a model monoclonal immunoglobulin G 1 (IgG1) antibody. Our previous work showed that M. arginini affects CHO cell growth profile, viability, nutrient consumption, oxygen use, and waste production at varying timepoints after M. arginini introduction to the culture. Careful evaluation of certain identified process parameters over time may be used to indicate mycoplasma contamination in CHO cell cultures in a bioreactor before detection from a traditional method. In this report, we studied the changes in the IgG1 product quality produced by CHO cells considered to be induced by the M. arginini contamination events. We observed changes in critical quality attributes correlated with the duration of contamination, including increased acidic charge variants and high mannose species, which were further modeled using principal component analysis to explore the relationships among M. arginini contamination, CHO cell growth and metabolites, and IgG1 product quality attributes. Finally, partial least square models using NIR spectral data were used to establish predictions of high levels (≥10(4) colony‐forming unit [CFU/ml]) of M. arginini contamination, but prediction of levels below 10(4) CFU/ml were not reliable. Contamination of CHO cells with M. arginini resulted in significant reduction of antibody product quality, highlighting the importance of rapid microbiological testing and mycoplasma testing during particularly long upstream bioprocesses to ensure product safety and quality. John Wiley and Sons Inc. 2020-06-04 2020-09 /pmc/articles/PMC7496122/ /pubmed/32436993 http://dx.doi.org/10.1002/bit.27436 Text en © 2020 The Authors. Biotechnology and Bioengineering published by Wiley Periodicals LLC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ARTICLES
Fratz‐Berilla, Erica J.
Angart, Phillip
Graham, Ryan J.
Powers, David N.
Mohammad, Adil
Kohnhorst, Casey
Faison, Talia
Velugula‐Yellela, Sai Rashmika
Trunfio, Nicholas
Agarabi, Cyrus
Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
title Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
title_full Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
title_fullStr Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
title_full_unstemmed Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
title_short Impacts on product quality attributes of monoclonal antibodies produced in CHO cell bioreactor cultures during intentional mycoplasma contamination events
title_sort impacts on product quality attributes of monoclonal antibodies produced in cho cell bioreactor cultures during intentional mycoplasma contamination events
topic ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496122/
https://www.ncbi.nlm.nih.gov/pubmed/32436993
http://dx.doi.org/10.1002/bit.27436
work_keys_str_mv AT fratzberillaericaj impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT angartphillip impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT grahamryanj impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT powersdavidn impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT mohammadadil impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT kohnhorstcasey impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT faisontalia impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT velugulayellelasairashmika impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT trunfionicholas impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents
AT agarabicyrus impactsonproductqualityattributesofmonoclonalantibodiesproducedinchocellbioreactorculturesduringintentionalmycoplasmacontaminationevents